What is Rochester Dermatologic Surgery?
Led by Dr. Sherrif Ibrahim, Rochester Dermatologic Surgery operates at the intersection of advanced surgical oncology and aesthetic medicine. The clinic is recognized for its expertise in Mohs micrographic surgery, a gold-standard treatment for skin cancer, while simultaneously providing a comprehensive suite of procedural and cosmetic dermatological services. By integrating high-acuity surgical care with elective aesthetic treatments, the practice maintains a diversified revenue model that appeals to both medically necessary and elective patient demographics. The organization emphasizes patient safety and clinical excellence, positioning itself as a premier provider within the regional healthcare landscape.
How much funding has Rochester Dermatologic Surgery raised?
Rochester Dermatologic Surgery has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Rochester Dermatologic Surgery
PPP
Public-Private Partnership
What's next for Rochester Dermatologic Surgery?
The influx of capital from this late-stage funding round is expected to catalyze the next phase of growth for Rochester Dermatologic Surgery. Strategic priorities likely include the scaling of surgical capacity, the adoption of cutting-edge dermatological technologies, and the potential expansion of its aesthetic service portfolio. As the practice navigates the evolving healthcare environment, this financial backing provides the necessary liquidity to optimize patient care workflows and potentially explore new clinical locations. By leveraging this investment, the firm is well-positioned to maintain its competitive advantage in the specialized dermatology sector while continuing to deliver high-quality outcomes for its patient base.
See full Rochester Dermatologic Surgery company page
